Article
Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.
Journal of the Egyptian National Cancer Institute - 14 Sept 2026
Mahato Sumit, Mudgal Shiv, Singh Harminder, Varikasuvu Seshadri Reddy, Kumar Hansraj, Thankachan Jameema, Kumar Subodh
Abstract excerpt
BACKGROUND: The optimal first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for EGFR-mutant advanced non-small cell lung cancer (NSCLC) remains uncertain due to the availability of multiple generations of TKIs and limited head-to-head comparisons. METHODS: A systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) was conducted comparing first,...
Read the complete abstract on PubMedTopics
- Humans
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Protein Kinase Inhibitors